申请人:Blumenfeld Marta
公开号:US20120220633A1
公开(公告)日:2012-08-30
HPV inhibitors with formula (I) where G
1
represents a hydrocarbonated bond or chain possibly substituted by one or two alkyl groups, G
2
represents a group (see formula Ia+Ib) or R represents a hydrogen, an alkyl, halogenoalkyl, or a prodrug radical such as carbamate, acetyl or dialkylaminomethy, G represents a bond or a hydrocarbonated chain possibly substituted by one or two alkyls, W represents an oxygen or sulphur, R
1
and R
2
each represent a group chosen from among hydrogen, halogen, hydroxyl, thio, alkoxy, halogenoalkoxy, alkylthis, halogenoalkylthio, amino, monoalkylamino, dialkylamino, cycloalkyl, alkyl or halogenoalkyl, R3 represents an acid or a prodrug radical of the acid function or a bioisotere of the acid function, A represents an aryl, cycloalkyl, cycloalkenyl or a heterocycle with 6 chains, each possibly substituted, and pharmaceutically acceptable salts.
具有公式(I)的HPV抑制剂,其中G1表示一个碳氢化合键或链,可能被一个或两个烷基取代,G2表示一个基团(见公式Ia+Ib)或R表示氢、烷基、卤代烷基或前药基如氨基甲酸酯、乙酰或二烷基氨基甲基,G表示一个键或一个碳氢化合链,可能被一个或两个烷基取代,W表示氧或硫,R1和R2分别表示从氢、卤、羟基、硫代、烷氧基、卤代烷氧基、烷基硫、卤代烷基硫、氨基、单烷基氨基、二烷基氨基、环烷基、烷基或卤代烷基中选择的基团,R3表示酸或酸功能的前药基或生物同位素,A表示苯基、环烷基、环烯基或具有6个链的杂环,每个可能被取代,以及药学上可接受的盐。